SC
CMPX icon

Steven Cohen’s Compass Therapeutics CMPX Stock Holding History

Steven Cohen’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
+686,577
New +$2.03M ﹤0.01% 2573
2023
Q2 		– Sell
-1,528
Closed -$5K – 2248
2023
Q1 		$5K Buy
+1,528
New +$6K ﹤0.01% 2080

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Steven Cohen's CMPX Position: Q2 2026 in Review

Steven Cohen opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 686,577 shares worth $1.5M. The stake represents ﹤0.01% of the portfolio and ranks #2573 among its holdings. This is a return to the name: Steven Cohen previously reported a position in CMPX as recently as Q1 2023.

Steven Cohen first reported a position in CMPX in Q1 2023 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Steven Cohen held 686,577 shares of Compass Therapeutics worth $1.5M as of Q2 2026.
  • Compass Therapeutics was a new Steven Cohen position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2573 holding.
  • Steven Cohen first reported a position in Compass Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.